GeneDx Holdings Corp. Investors With Losses Urged to Join Class Action
Legal counsel is urging investors in GeneDx Holdings Corp. who have sustained substantial losses to consider legal action. The deadline for investors seeking to become lead plaintiffs in a class action lawsuit is August 3, 2026.
Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GeneDx Holdings Corp. and is seeking investors who suffered significant losses. The lawsuit alleges that GeneDx and some of its top executives made materially false and misleading statements about the strategic and financial benefits of its acquisition of Fabric Genomics. Investors who purchased GeneDx common stock between April 16, 2025, and May 4, 2026, and experienced substantial losses are encouraged to contact the firm.
The core of the allegations centers on claims that GeneDx misrepresented the purported synergistic and financial advantages of acquiring Fabric Genomics. The complaint states that defendants allegedly concealed integration challenges and operational issues that negatively impacted the company's overall business, contradicting earlier positive statements.
GeneDx's stock price plummeted on May 4, 2026, after the company reported its first-quarter 2026 financial results. The company announced it missed revenue estimates for its testing lines and saw a decline in adjusted gross margins. Furthermore, GeneDx significantly lowered its full-year revenue guidance and recorded a $31.2 million impairment charge related to Fabric Genomics, wiping out nearly all the cash paid for the unit.
In the single trading session following these disclosures, GeneDx shares fell 49.2%, resulting in billions of dollars in shareholder value destruction. Investors who suffered significant losses and wish to explore their options are advised to contact Hagens Berman by the August 3, 2026, lead plaintiff deadline.